Enrollment Objective Achieved for Aspirin and Clopidogrel Patient Group of the On-X Life Technologies, Inc. Heart Valve Anticoagulation Clinical Study
7/26/2011 10:17:06 AM
AUSTIN, Texas--(BUSINESS WIRE)--On-X® Life Technologies, Inc. (On-X LTI) announced today that the enrollment objective for the Low-Risk Aortic Valve Patient Group has been achieved. The Prospective Randomized On-X Valve Anticoagulation Trial (PROACT) was initiated in 2006 and is being conducted at 36 centers throughout the United States and Canada. The purpose of the Low-Risk Patient Group of the PROACT clinical trial is to determine if lower-risk recipients of the On-X Aortic Valve can be safely maintained with aspirin and clopidogrel (Plavix®).